Dexmedetomidine Protects against Ischemia and Reperfusion-Induced Kidney Injury in Rats

Naren Bao and Di Dai

Department of Anesthesiology, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, China

Department of Laboratory Medicine, The First Hospital of China Medical University, 155 Nanjing North Street, Shenyang, China

Correspondence should be addressed to Di Dai; diana_dd@126.com

Received 5 March 2020; Accepted 24 March 2020; Published 3 April 2020

Guest Editor: Hongmei Jiang

Copyright © 2020 Naren Bao and Di Dai. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acute kidney injury (AKI), a clinical syndrome, is a sudden onset of kidney failure that severely affects the kidney tubules. One potential treatment is dexmedetomidine (DEX), a highly selective α₂-adrenoreceptor agonist that is used as an anesthetic adjuvant. It also has anti-inflammatory, neuroprotective, and sympatholytic qualities. The aim of this study was to establish whether DEX also offers protection against ischemia and reperfusion- (I/R-) induced AKI in rats. An intraperitoneal injection of DEX (25 μg/kg) was administered 30 min prior to the induction of I/R. The results indicate that in the I/R rats, DEX played a protective role by reducing the damage to the tubules and maintaining renal function. Furthermore, in response to I/R, the DEX treatment reduced the mRNA expression of TNF-α, IL-1β, IL-6, and MCP-1 in the kidney tissues and the serum levels of TNF-α, IL-1β, IL-6, and MCP-1. DEX also reduced the levels of oxidative stress and apoptosis in the tubular cells. These results indicate that in response to I/R kidney injury, DEX plays a protective role by inhibiting inflammation and tubular cell apoptosis, reducing the production of reactive oxygen species, and promoting renal function.

1. Introduction

Acute kidney injury (AKI), a clinical syndrome, is a sudden onset of kidney failure that severely affects the kidney tubules. One potential treatment is dexmedetomidine (DEX), a highly selective α₂-adrenoreceptor agonist that is used as an anesthetic adjuvant. It also has anti-inflammatory, neuroprotective, and sympatholytic qualities. The aim of this study was to establish whether DEX also offers protection against ischemia and reperfusion- (I/R-) induced AKI in rats. An intraperitoneal injection of DEX (25 μg/kg) was administered 30 min prior to the induction of I/R. The results indicate that in the I/R rats, DEX played a protective role by reducing the damage to the tubules and maintaining renal function. Furthermore, in response to I/R, the DEX treatment reduced the mRNA expression of TNF-α, IL-1β, IL-6, and MCP-1 in the kidney tissues and the serum levels of TNF-α, IL-1β, IL-6, and MCP-1. DEX also reduced the levels of oxidative stress and apoptosis in the tubular cells. These results indicate that in response to I/R kidney injury, DEX plays a protective role by inhibiting inflammation and tubular cell apoptosis, reducing the production of reactive oxygen species, and promoting renal function.
2. Materials and Methods

2.1. Animals and Experimental Design. The study observed the China Medical University’s guidelines for the use of laboratory animals. Approval was sought from and granted by the Ethics Committee on Animal Experiments of The First Hospital of China Medical University.

Eighteen healthy 7–8-week-old male Sprague-Dawley rats weighing 220–270 g were used. They were accommodated in a laboratory (22 °C ± 1 °C) in pathogen-free housing for one week prior to the experiment. Food and water were provided ad libitum until 12 h before the experiment. The food was then withdrawn; however, the water was available.

The rats were sedated and analogized with 10% chloral hydrate (0.3 ml/100 g) and 10 μg/kg sufentanil citrate (Renfu Pharmaceutical, China, Lot 81A06031) injected intraperitoneally (i.p.). To improve perioperative analgesia, 0.2% ropivacaine (AstraZeneca AB, Sweden) was used for local infiltration before surgical incision and after suture. The rats’ temperatures were measured, and they were sustained at 37 °C (±1°C) with a heat pad. The heart rates were monitored with subcutaneous electrodes. Arterial pressure was invasively monitored by a 24 G trocar that was placed in the left femoral artery. The exclusion criteria were applied to the rats that had heart rates slower than 200 beats per min (bpm) for more than 5 min or mean blood pressures (MAP) less than 55 mmHg. To induce renal I/R injury, the right renal pedicle was clamped for 45 min, and the left was surgically removed.

2.2. Renal Histology. The kidneys were postfixed with 10% buffered formalin, dehydrated in graded ethanol solutions, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Acute tubular necrosis was graded on a 0 to 4 scale on the basis of the damage to the cortex or outer medulla: 0 = normal, 1 = minimal damage (<5% involvement), 2 = mild damage (5–25% involvement), 3 = moderate damage (25–75% involvement), and 4 = severe damage (>75% involvement) [10].

2.3. Renal Function. Serum creatinine (CREA) and serum urea nitrogen were quantified with a UniCel DxC800 Synchron device (Beckman, USA). Standard enzyme immunoassay kits (BioPorto Diagnostics, Gentofte, Denmark) were used to establish the serum concentrations of the neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C.

2.4. Reverse Transcription Polymerase Chain Reaction. Reverse transcription polymerase chain reaction (RT-PCR) was used to determine the expression levels of TNF-α, IL-1β, IL-6, and MCP-1 in the kidneys. The total cellular RNA was extracted with TRIzol (Invitrogen), and the cDNA was synthesized with a Moloney murine leukemia virus (M-MLV) reverse transcription kit (Promega). Quantitative real-time PCR was performed through the use of an IQ SYBR Green Supermix reagent (Bio-Rad, USA) with a Bio-Rad real-time PCR machine. The manufacturer’s instructions were followed. The data were analyzed by the use of the ΔΔCT method. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene against which the expression levels of the target genes were normalized. Table 1 presents the primer sequences.

2.5. Kidney Oxidative Stress Analysis. A homogenate of the kidney tissue was made to measure the concentration of glutathione (GSH) and malondialdehyde (MDA). The homogenate was also used to identify superoxide dismutase (SOD) antioxidant enzyme activity. The manufacturer’s instructions for the corresponding assay kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) were followed.

| Primers        | Sequences                          |
|----------------|------------------------------------|
| TNF-α Forward  | 5′-CCC GGA ATG CCT GAGTG-3′         |
| TNF-α Reverse  | 5′-CGC CCC GGC CCT CCA AAT AAAT-3′ |
| IL-1β Forward  | 5′-GCC CAT CCT TGT TGA CTC AT-3′    |
| IL-1β Reverse  | 5′-AGG CCA CAG GTA TTT TGT CG-3′   |
| IL-6 Forward   | 5′-TCT CGA GCC CAC CAG GAA CGA-3′  |
| IL-6 Reverse   | 5′-AGG GAA GGC AGT GGC TGT CA-3′   |
| MCP-1 Forward  | 5′-AGC ATC CAC GTG CTG TCT C-3′    |
| MCP-1 Reverse  | 5′-GAT CAT CTT GCC AGT GAA TGAG-3′ |
| GAPDH Forward  | 5′-AGG TCG GTG TGA ACG GAT TTG-3′  |
| GAPDH Reverse  | 5′-TGT AGG AGA CCA TGT AGT GGA TTG-3′ |
2.6. Serum Inflammatory Cytokine Analysis. The serum inflammatory cytokines were measured through the use of a commercial enzyme-linked immunosorbent assay (ELISA) kit from Nanjing Jiancheng Bioinstitute (Nanjing, Jiangsu, China) and a microplate reader at 450 nm (Thermo Scientific, Waltham, MA). The manufacturer’s guidelines were followed.

2.7. Terminal Deoxynucleotidyl Transferase Deoxyuridine Triphosphate Nick-End Labeling (TUNEL) Assay. To detect the apoptotic tubular epithelial cells, an in situ TUNEL assay was used in accordance with the manufacturer’s instructions (In Situ Cell Death Detection Kit, POD, Roche, Switzerland). The sections that had been fixed in paraflin were dewaxed. They were then rehydrated with xylene and a graded series of ethanol and double-distilled water. The sections were treated with proteinase K (20 μg/ml) at room temperature for 15 min before being rinsed twice with phosphate buffer saline (PBS). After the slide was dried, 50 μl of TUNEL reaction mixture was applied. The slides were incubated at 37°C in a humidified chamber for 60 min and then rinsed three times with PBS. Converter-POD (50 μl) was added to the specimen, and a coverslip was applied before incubation at 37°C in a humidified chamber for 30 min. The samples were again rinsed three times with PBS and then stained with a diaminobenzidine (DAB) substrate (Zhongshan, Beijing, China). After 10 min, the DAB was removed by being rinsed three times with PBS. Hematoxylin or methyl green stains were applied and then rinsed with tap water almost immediately. ImageJ software (version 1.38; National Institutes of Health, Rockville, MD) was used for counting the number of TUNEL-positive cells in an objective grid in regions of 10 randomly selected sections. A 40x objective lens was used for the counts, which were performed by a researcher who was blinded to the experiment aims. The data from the average of these 10 counts were analyzed.

2.8. Statistical Analysis. The data were analyzed in IBM SPSS Statistics for Windows, version 22.0 (SPSS Inc., Chicago, IL, USA). The results are presented as means and standard deviation (SD). One-way analysis of variance (ANOVA) was used to compare multiple sets of data. Statistical significance was set at p < 0.05. The graphs were created in GraphPad Prism 7.00 (GraphPad Inc., San Diego, CA, USA).

3. Results
To confirm the effects of DEX on I/R-induced renal injury, 25 μg/kg of DEX was administered by i.p. injection 30 min before I/R. Figure 1 presents the histological images through which kidney injury was determined. The evidence provided by the hematoxylin and eosin (H&E) stains indicates that the

Figure 1: Dexmedetomidine (DEX) preconditioning showed renoprotective effects histologically (10x). Renal injury was inflicted in the experimental group by removing the left kidney and clamping the right renal artery for 45 min (renal ischemia-reperfusion (I/R)). In the sham control group, both renal pedicles were dissected without occlusion. DEX was administered 30 min prior to ischemia. Representative microphotographs were taken from (a) the sham control group, (b) the I/R group, (c) the DEX (25 μg/kg)+I/R group, and (d) the quantification of the histological scores following I/R in rats. The histological damages were indicated by black arrows. The data are the mean ± SD (n = 6). *p < 0.05.
histological injuries to the I/R rats’ kidneys included focal renal hemorrhage, focal tubular necrosis, neutrophil infiltration, and vacuolar degeneration of the renal tubular epithelial cells (p < 0.05). The histological damage in the DEX-treated rats was lesser (p < 0.05) than that in the I/R rats. As is shown in Figure 2, the marked increase in serum CREA (p < 0.05) and urea nitrogen (p < 0.05) was indicative of I/R-induced renal dysfunction. However, these serum markers were significantly lower (p < 0.05) in the DEX-treated rats than in the I/R rats. This suggests that the renal function in the DEX-treated rats was maintained at least (p < 0.05) than that in the I/R rats. Furthermore, the serum NGAL and cystatin C levels in the I/R-induced rats were significantly higher (p < 0.05) than those in the sham group. However, they were significantly lower (p < 0.05) in the DEX-treated rats than in the I/R-induced rats (Figure 2).

The effects of DEX on oxidative stress were also evaluated. As is illustrated in Figure 3, the MDA concentrations in the I/R-induced rats were significantly higher (p < 0.05) than those in the sham group. However, in the I/R rats treated with DEX, the levels of oxidative stress were lower (p < 0.05) than those in the I/R rats. The GSH and SOD activity levels in the I/R group were significantly lower (p < 0.05) than those in the sham control. Nevertheless, the DEX concentration and SOD activity levels in the I/R group treated with DEX were significantly higher (p < 0.05) than those in the I/R group.

The effects of DEX on the expression of proinflammatory cytokines were evaluated. The RT-PCR results for the kidney samples indicated that the expression levels of IL-1β, IL-6, MCP-1, and TNF-α mRNA were significantly higher (p < 0.05) in the I/R-induced rats than in the controls (Figure 4). However, DEX exerted a modulatory effect. The mRNA expression of IL-1β, IL-6, MCP-1, and TNF-α (p < 0.05) in the kidney tissues of the rats that received DEX treatment was lower than that in the I/R-induced rats. The serum levels of IL-1β, IL-6, MCP-1, and TNF-α in the I/R rats were considerably higher than those in the DEX-treated I/R rats (p < 0.05). The serum levels of IL-1β, IL-6, MCP-1, and TNF-α (p < 0.05) in the rats that received DEX treatment were lower than those in the I/R-induced rats. This suggests that in the case of I/R injury, DEX exerts an inhibitory effect on the expression of inflammatory cytokines.

The available evidence suggests that the pathogenesis of I/R injury is aggravated by the apoptosis of the tubular cells. Thus, the effect of DEX on tubular epithelial cell apoptosis in the I/R-induced rats was explored. The results of the TUNEL assay revealed that I/R injury was associated with a significant increase (p < 0.05) in the level of apoptosis in these epithelial cells. In contrast, there were fewer apoptotic cells in the kidney samples from the DEX-treated rats (p < 0.05) than those from the I/R group (Figure 5).

4. Discussion

A sequela of cardiovascular and transplant surgery or shock is renal I/R injury that causes AKI. This results in longer hospital stays and even death [11]. The present study has
demanded that pretreatment with DEX helps to maintain renal morphology and function in cases of I/R injury. When kidney I/R occurred, the levels of inflammatory mediators circulating in the blood were reduced, and the kidneys experienced less oxidative stress as a consequence of the administration of DEX. These findings suggest that DEX might be an appropriate pharmaceutical intervention to reduce acute injury-induced kidney damage.

Among the qualities of DEX are its anesthetic-sparing effect and facilitation of hemodynamic stability. Consequently, DEX is frequently administered as a sedative in perioperative and intensive care medicine. It is also applied as an anesthetic adjuvant [12]. DEX has wide clinical applications because its analgesic, hemodynamic, sedative, and sympatholytic qualities make it particularly useful for perioperative patients. Other features are its anti-inflammation, antioxidant, and antiapoptotic effects on the brain, heart, lungs, and kidneys [13, 14]. The results of several animal model studies indicate that DEX also offers protection against I/R injury to the kidney [12, 15]. Other studies have highlighted the beneficial role of DEX in preventing renal injury in patients undergoing cardiovascular and other major surgical procedures [16]. These findings supplement those of earlier studies that reported significant increases in the CREA and BUN levels following I/R injury. This suggests impaired renal function. An examination of the histopathological evidence indicates that I/R causes kidney injury; however, DEX pretreatment can be mitigative.

A surfeit of oxygen-free radicals is produced by organisms in a state of stress. This disrupts the delicate balance between the oxidation and antioxidant systems [17]. The results of this study indicate that the MDA levels, an important biomarker of oxidative damage, are reduced and the GSH and SOD levels are increased by DEX. MDA is a useful indirect indicator of the extent of free radical-induced damage [18]. In contrast, GSH and SOD are important antioxidants [19]. The results suggest that I/R diminished the antioxidant defense system by increasing the MDA levels and reducing the GSH and GSH enzyme activity. This suggests that I/R could induce oxidative stress, which might be significant in the pathogenesis of AKI. The DEX treatment helped to protect against oxidative stress suggesting that it has antioxidative effects [20]. Therefore, DEX could provide protection against I/R-induced AKI.

Another manifestation of I/R injury is a heightened inflammatory response [21, 22]. This response aggravates the conditions because the macrophages, T cells, and other inflammatory mediators are recruited to the tissues injured by I/R [21, 22]. As the results of the tissue samples obtained from the kidneys of I/R-injured rats in this study have demonstrated, the expression of IL-1β, IL-6, MCP-1, and TNF-α mRNA was elevated. In contrast, the renal tissue samples from the rats that had received DEX following I/R exhibited lower IL-1β, IL-6, MCP-1, and TNF-α mRNA expression. Relationships among renal morphology, the serum levels of inflammatory mediators, and the state of cell apoptosis were found. The pathogenesis and progression of I/R injury are influenced by the proinflammatory cytokines, including IL-1β, IL-6, MCP-1, and TNF-α [23, 24]. DEX not only acts locally on the kidney’s α2-adrenoceptors but also influences the anti-inflammatory reactions, thereby mitigating the damaging effects of I/R on the kidney.

Apoptosis, also known as programmed cell death, is a critical mechanism for maintaining cell stability; however, too much can damage the body [25]. Usually, apoptosis, an early event in kidney I/R injury, interacts with the subsequent inflammation and kidney injury [26]. In the present study, a
significantly higher number of TUNEL-positive cells were retrieved from the rats with the I/R-injured kidneys than from those that received the DEX intervention. Studies have found that TNF-α causes injury to the kidneys [27, 28]. DEX might protect against AKI following I/R by stimulating an antiapoptotic effect.

The data obtained from this study demonstrate that DEX exerts a protective effect against I/R injury in rats by
inhibiting tubular cell apoptosis and inflammation, lowering ROS production, and promoting renal function. These results suggest that DEX may play a role in the treatment of I/R-initiated AKI. However, DEX is not without side effects; through parasympathetic activation, it can contribute to bradycardia. How DEX can be best exploited to protect vital organs has yet to be established. Further research into its applications is justified.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Authors’ Contributions

Naren Bao finished the first draft of the manuscript; Di Dai critically revised the manuscript. All the authors approved the submission of the manuscript.

Acknowledgments

This work was supported by the Science and Technology Research Project of Liaoning Provincial Education Department (LK201651).

References

[1] C. Hobson, T. Ozrazgat-Baslanti, A. Kuxhausen et al., “Cost and mortality associated with postoperative acute kidney injury,” Annals of Surgery, vol. 261, no. 6, pp. 1207–1214, 2015.
[2] M. V. Wohlauer, A. Sauaia, E. E. Moore, C. C. Burlew, A. Banerjee, and J. Johnson, “Acute kidney injury and post-trauma multiple organ failure,” Journal of Trauma and Acute Care Surgery, vol. 72, no. 2, pp. 373–380, 2012.
[3] B. Khoundabi, A. Kazemnejad, M. Mansourian, S. M. Hashemi, and M. Kazempoor Dizaji, “Acute kidney injury risk factors for ICU patients following cardiac surgery: the application of joint modeling,” Trauma Monthly, vol. 21, no. 4, article e23749, 2016.
[4] N. M. Abogresha, S. M. Greish, E. Z. Abdelaziz, and W. F. Khalil, “Remote effect of kidney ischemia-reperfusion injury on pancreas: role of oxidative stress and mitochondrial apoptosis,” Archives of Medical Science, vol. 12, no. 2, pp. 252–262, 2016.
[5] Q. Ma, Y. Xu, L. Tang et al., “Astragalus polysaccharide attenuates cisplatin-induced acute kidney injury by suppressing oxidative damage and mitochondrial dysfunction,” BioMed
Enhanced nitric oxide generation from nitric oxide synthases as the cause of increased peroxynitrite formation during acute restraint stress: effects on carotid responsiveness to angiotensinergic stimuli in type-1 diabetic rats, European Journal of Pharmacology, vol. 783, pp. 11–22, 2016.

Dehydrins impart protection against oxidative stress and in inflammation, European Journal of Pharmacology, vol. 772, 11 pages, 2010.

Critical Care, vol. 13, no. 4, p. R136, 2009.

Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and oxidative stress in NLRC5 deficient mice, Biochemical and Biophysical Research Communications, vol. 493, no. 2, pp. 1143–1150, 2017.

Erzhi pill® repairs hippocampal cell amelioration of renal ischemia/reperfusion injury, Stem Cells and Development, vol. 21, no. 7, pp. 1187–1199, 2012.

Mediators of Inflammation, vol. 20, Article ID 2851349, 12 pages, 2020.

H. Tian, Y. Lu, S. P. Shah, Q. Wang, and S. Hong, "14S,21R-Dihydroxy-docosahexaenoic acid treatment enhances mesenchymal stem cell amelioration of renal ischemia/reperfusion injury," Stem Cells and Development, vol. 21, no. 7, pp. 1187–1199, 2012.

Dexmedetomidine reduces propofol and remifentanil requirements during bisppectral index-guided closed-loop anesthesia: a double-blind, placebo-controlled trial, Anesthesia and Analgesia, vol. 115, no. 5, pp. 946–955, 2014.

Sedation improves early outcome in severely septic Sprague Dawley rats, Critical Care, vol. 13, no. 4, p. R136, 2009.

D. C. Ponticelli, "Ischaemia-reperfusion injury: a major protagonist in kidney transplantation," Nephrology, Dialysis, Transplantation, vol. 29, no. 6, pp. 1134–1140, 2014.

Dexmedetomidine alleviates hyperoxia-induced acute lung injury via inhibiting NLRP3 inflammasome activation, Cellular Physiology and Biochemistry, vol. 42, no. 5, pp. 1907–1919, 2017.

P. Jaholnski, B. O. Howden, D. A. Rae, C. S. Birrell, V. C. Marshall, and J. Tange, "An experimental model for assessment of renal recovery from warm ischemia," Transplantation, vol. 35, no. 3, pp. 198–204, 1983.

C. Ponticelli, "Ischaemia-reperfusion injury: a major protagonist in kidney transplantation," Nephrology, Dialysis, Transplantation, vol. 29, no. 6, pp. 1134–1140, 2014.

J. W. Sleigh, S. Vacas, A. M. Flexman, and P. O. Talke, "Electroencephalographic arousal patterns under dexmedetomidine sedation," Anesthesia and Analgesia, vol. 127, no. 4, pp. 951–959, 2018.

M. Mahmoud, S. Sadhasivam, S. Salisbury et al., "Susceptibility of transcranial electric motor-evoked potentials to varying targeted blood levels of dexmedetomidine during spine surgery," Anesthesiology, vol. 112, no. 6, pp. 1364–1373, 2010.

M. Le Guen, N. Liu, F. Tounou et al., "Dexmedetomidine reduces propofol and remifentanil requirements during bispectral index-guided closed-loop anesthesia: a double-blind, placebo-controlled trial," Anesthesia and Analgesia, vol. 118, no. 5, pp. 946–955, 2014.

H. Qiao, R. D. Sanders, D. Ma, X. Wu, and M. Maze, "Sedation improves early outcome in severely septic Sprague Dawley rats," Critical Care, vol. 13, no. 4, p. R136, 2009.

J. D. Moreira, L. Pernomian, M. S. Gomes et al., "Enhanced nitric oxide generation from nitric oxide synthases as the cause of increased peroxynitrite formation during acute restraint stress: effects on carotid responsiveness to angiotensinergic stimuli in type-1 diabetic rats," European Journal of Pharmacology, vol. 783, pp. 11–22, 2016.

T. Halder, G. Upadhyaya, C. Basak, A. Das, C. Chakraborty, and S. Ray, "Dehydrins impart protection against oxidative stress in transgenic tobacco plants," Frontiers in Plant Science, vol. 9, p. 136, 2018.

H. Yaribeygi, M. T. Mohammadi, and A. Sahebkar, "PPAR-α agonist improves hyperglycemia-induced oxidative stress in pancreatic cells by potentiating antioxidant defense system," Drug Research, vol. 68, no. 6, pp. 355–360, 2018.

Z. Chen, T. Ding, and C. G. Ma, "Dexmedetomidine (DEX) protects against hepatic ischemia/reperfusion (I/R) injury by suppressing inflammation and oxidative stress in NLRC5 deficient mice," Biochemical and Biophysical Research Communications, vol. 493, no. 2, pp. 1143–1150, 2017.

Y. Nozaki, K. Kinoshita, S. Hino et al., "Signaling rho-kinase mediates inflammation and apoptosis in T cells and renal tubules in cisplatin nephrotoxicity," American Journal of Physiology Renal Physiology, vol. 308, no. 8, pp. F899–F909, 2015.

S. Malik, K. Suchal, N. Gamad, A. K. Dinda, D. S. Arya, and J. Bhatia, "Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis," European Journal of Pharmacology, vol. 748, pp. 54–60, 2015.

C. Z. Li, H. H. Jin, H. X. Sun et al., "Eriodictyol attenuates cisplatin-induced kidney injury by inhibiting oxidative stress and inflammation," European Journal of Pharmacology, vol. 772, pp. 124–130, 2016.

N. M. Elsherbiny, M. A. Eladl, and M. M. Al-Gayyar, "Renal protective effects of arjunolic acid in a cisplatin-induced nephrotoxicity model," Cytokine, vol. 77, pp. 26–34, 2016.

B. G. Zhou, H. M. Zhao, X. Y. Lu et al., "Erzhi pill® repairs experimental liver injury via TSC/mTOR signaling pathway inhibiting excessive apoptosis," Evidence-based Complementary and Alternative Medicine, vol. 2017, Article ID 5653643, 15 pages, 2017.

H. Tian, Y. Lu, S. P. Shah, Q. Wang, and S. Hong, "14S,21R-Dihydroxy-docosahexaenoic acid treatment enhances mesenchymal stem cell amelioration of renal ischemia/reperfusion injury," Stem Cells and Development, vol. 21, no. 7, pp. 1187–1199, 2012.

M. D. Sanchez-Niño, A. Benito-Martin, S. Gonçalves et al., "TNF-α superfamily: a growing saga of kidney injury modulators," Mediators of Inflammation, vol. 2010, Article ID 182958, 11 pages, 2010.

Y. Wang, R. Wang, B. Yao et al., "TNF-α suppresses sweat gland differentiation of MSCs by reducing FTO-mediated m6A-demethylation of Nanog mRNA," Science China Life Sciences, vol. 63, no. 1, pp. 80–91, 2020.